Table 1.
Demographics and clinical characteristics of patients.
| Variable | N (%) |
|---|---|
| Total | 2,293 |
| Gender | |
| Male | 958 (41.8) |
| Female | 1,335 (58.2) |
| Age | |
| Median | 69 (21–90) |
| STD | 14.78 |
| Race | |
| White | 2,004 (87.4) |
| African American | 188 (8.2) |
| Others | 101 (4.4) |
| Year of diagnosis | |
| 2010 | 413 (18.0) |
| 2011 | 566 (24.7) |
| 2012 | 633 (27.6) |
| 2013 | 681 (29.7) |
| Charlson–Deyo score | |
| 0 | 1,540 (67.2) |
| 1 | 537 (23.4) |
| 2+ | 216 (9.4) |
| Site | |
| Appendix | 8 (0.4) |
| Cecum | 621 (27.1) |
| Ascending colon | 746 (32.5) |
| Hepatic flexure | 143 (6.2) |
| Transverse colon | 301 (13.1) |
| Splenic flexure | 80 (3.5) |
| Descending colon | 115 (5.0) |
| Sigmoid colon | 222 (9.7) |
| Overlapping | 36 (1.6) |
| Not otherwise specified | 21 (0.9) |
| Surgery at primary site | |
| Partial colectomy | 487 (21.2) |
| Subtotal colectomy/hemicolectomy | 1,722 (75.1) |
| Total colectomy | 42 (1.8) |
| Total proctocolectomy | 10 (0.4) |
| Unknown | 32 (1.4) |
| Grade | |
| Well differentiated/moderately differentiated | 1,540 (67.2) |
| Poorly differentiated/undifferentiated | 753 (32.8) |
| Pathological T stage | |
| T3 | 1,957 (85.3) |
| T4 | 321 (14.0) |
| Risk group per study | |
| High risk | 676 (29.5) |
| Not high risk | 1,617 (70.5) |
| High-risk features a | |
| T4 | 321 (14.0) |
| LVI | 329 (14.3) |
| <12 lymph node removed | 89 (3.9) |
| Positive margin | 69 (3.0) |
| Systemic/surgery sequence | |
| No systemic therapy | 1,862 (81.2) |
| Systemic therapy after surgery | 431 (18.8) |
| Chemotherapy | |
| No chemotherapy | 1,862 (81.2) |
| Single-agent chemotherapy | 108 (4.7) |
| Multiagent chemotherapy | 292 (12.7) |
| Chemotherapy type and number of agents not documented | 31 (1.4) |
a
High-risk features not mutually exclusive.